Relative change from baseline in percent-predicted FEV1 did not differ significantly between ataluren and placebo at week 48 ( -2.5 % vs -5.5 % ; difference 3.0 % [ 95 % CI -0.8 to 6.3 ] ; p = 0.12 ) .